Impact of Calory Restriction and Biofeedback on Endocrine and Mental Health

Sponsor
Medical University of Vienna (Other)
Overall Status
Completed
CT.gov ID
NCT04848948
Collaborator
(none)
44
1
4
6.1
7.2

Study Details

Study Description

Brief Summary

Backgroup/relevance: Overweight and obesity, defined by a respective body mass index of above 25 and 30 kg/m2, are getting increasingly common in all regions of the world. Obesity is currently estimated to be present in more than 10% of the global population while overweight roughly reached an estimate of 40% in 2016.

Overweight dramatically increases the risk for a wide range of disorders such as diabetes mellitus and other metabolic and cardiovascular disorders subsumed under the term metabolic syndrome, increasing the risk for life-threatening cardiovascular events such as myocardial infarction and stroke. Similar to other chronic diseases such as mental health disorders, prescribing medication was oftentimes insufficient and should be complemented by patient empowerment to reach sufficient treatment adherence and control of lifestyle factors. Thereby, overweight and obesity can easily be challenged by patients themselves without pharmacological intervention.

Overweight may place central in the crossroad between metabolic and mental health for several reasons. Excessive body fat is known to cause subclinical inflammation that was also associated with many psychiatric disorders such as major depression. Similarly, the hypothalamic-pituitary-adrenal axis relevant for stress response was shown to be dysregulated in both metabolic and mental health disorders.

Study design: In this study, non-pharmacological interventions are applied in healthy women with overweight or obesity and self-perceived psychological stress. Women staying at the "la pura" women´s health resort (www.lapura.at/) are invited to partake in the study and receive a short-term intervention of calory restriction. Thereby, either F.X. Mayr or very-low-calory-diet (VLCD) will be applied, reducing calory intake to 700-800 kcal/die. Following random assigment to four treatment arms, half of the women also receive a 7-session clinical-psychological intervention consisting of biofeedback, individualized psycho-education on stress prevention and mindlessness training.

Women are assessed at baseline and after two weeks of interventions for metabolic parameters such as insulin functioning, anthropometric parameters such as body weight and body fat, blood parameters such as sex hormones, fat metabolism and liver function, parameters of neuroplasticity such as brain derived neurotrophic factor (BDNF), as well as psychological and biological stress correlates and mental health symptom dimensions.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Calory Restriction (F.X. Mayr & VLCD)
  • Behavioral: Biofeedback
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
44 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Effects of Short-term Calory Restriction and Biofeedback on Anthropometric and Metabolic Parameters as Well as Biological and Psychological Stress Correlates in Healthy Women
Actual Study Start Date :
Sep 1, 2019
Actual Primary Completion Date :
Mar 4, 2020
Actual Study Completion Date :
Mar 4, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: F.X.Mayr & Biofeedback

two weeks of F.X. Mayr diet and biofeedback

Behavioral: Calory Restriction (F.X. Mayr & VLCD)
VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates). F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.

Behavioral: Biofeedback
Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.

Active Comparator: F.X.Mayr

two weeks of F.X. Mayr diet

Behavioral: Calory Restriction (F.X. Mayr & VLCD)
VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates). F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.

Experimental: VLCD & Biofeedback

two weeks of very low calorie diet and biofeedback

Behavioral: Calory Restriction (F.X. Mayr & VLCD)
VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates). F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.

Behavioral: Biofeedback
Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.

Active Comparator: VLCD

two weeks of very low calorie diet

Behavioral: Calory Restriction (F.X. Mayr & VLCD)
VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates). F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.

Outcome Measures

Primary Outcome Measures

  1. PSS score [Baseline, changes over two weeks]

    Perceived Stress Scale total score

  2. BODI [Baseline, changes over two weeks]

    buron-out-diagnostic-inventory scores, 4 summary items and 3 stress self-ratings

  3. BSI [Baseline, changes over two weeks]

    Brief Symptom Inventory, 9 dimensional subscores and global severity score

  4. waist-to-height ratio [Baseline]

    Anthropometric parameter

  5. HbA1c [Baseline]

    Glycated hemoglobin

  6. HOMA-IR [Baseline]

    Functional parameter for insulin resistance

  7. Matsuda Index [Baseline]

    Functional parameter for insulin sensitivity

  8. Body mass index [Baseline, changes over two weeks]

    weight in relation to height

  9. HRV [Baseline, changes over two weeks]

    heart rate variability

Secondary Outcome Measures

  1. Body fat [Baseline, changes over two weeks]

    measured by bioimpedance analysis

  2. lean mass [Baseline, changes over two weeks]

    measured by bioimpedance analysis

  3. Phase angle [Baseline, changes over two weeks]

    ratio of reactance versus electric resistance, measured by bioimpedance analysis

  4. Resistin [Baseline, changes over two weeks]

    Adipocines

  5. Leptin [Baseline, changes over two weeks]

    Adipocines

  6. Secretagogin [Baseline, changes over two weeks]

    Adipocines

  7. Adiponectin [Baseline, changes over two weeks]

    Adipocines

  8. BDNF [Baseline, changes over two weeks]

    brain derived neurotrophic factor

  9. Estrogen [Baseline, changes over two weeks]

    Sex hormone

  10. Testosterone [Baseline, changes over two weeks]

    Sex hormone

  11. Luteinizing hormone [Baseline, changes over two weeks]

    Sex hormone

  12. Follicle-stimulating hormone [Baseline, changes over two weeks]

    Sex hormone

  13. Total cholesterol [Baseline, changes over two weeks]

    Lipid metabolism

  14. High-density lipoprotein (HDL) [Baseline, changes over two weeks]

    Lipid metabolism

  15. BSRI [Baseline]

    Bem sex role inventory, female, male, neutral scores

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • women willing to undergo two-weeks of calory restriction

  • at least 18 years of age

Exclusion Criteria:
  • currently pregnant

  • any acute or a severe chronic illness

Contacts and Locations

Locations

Site City State Country Postal Code
1 VAMED Gender Insitute Gars am Kamp Niederösterreich Austria 3571

Sponsors and Collaborators

  • Medical University of Vienna

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alexandra Kautzky-Willer, Prof.Dr., Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT04848948
Other Study ID Numbers:
  • 2020-GI-01
First Posted:
Apr 19, 2021
Last Update Posted:
Apr 19, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2021